These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27325603)

  • 1. Disability progression in aggressive multiple sclerosis.
    Menon S; Zhu F; Shirani A; Oger J; Freedman MS; Tremlett H
    Mult Scler; 2017 Mar; 23(3):456-463. PubMed ID: 27325603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterising aggressive multiple sclerosis.
    Menon S; Shirani A; Zhao Y; Oger J; Traboulsee A; Freedman MS; Tremlett H
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1192-8. PubMed ID: 23744892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).
    Shirani A; Zhao Y; Kingwell E; Rieckmann P; Tremlett H
    Mult Scler; 2012 Apr; 18(4):442-50. PubMed ID: 21952097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses add to permanent disability in relapsing multiple sclerosis patients.
    Koch-Henriksen N; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural, innate improvements in multiple sclerosis disability.
    Tremlett H; Zhu F; Petkau J; Oger J; Zhao Y;
    Mult Scler; 2012 Oct; 18(10):1412-21. PubMed ID: 22736751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of multiple sclerosis relapses on progression diminishes with time.
    Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
    Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.
    Zhang T; Kingwell E; De Jong HJ; Zhu F; Zhao Y; Carruthers R; Petkau J; Gustafson P; Oger J; Tremlett H
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1150-1159. PubMed ID: 27211481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
    Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired health-related quality of life predicts progression of disability in multiple sclerosis.
    Benito-León J; Mitchell AJ; Rivera-Navarro J; Morales-González JM
    Eur J Neurol; 2013 Jan; 20(1):79-86. PubMed ID: 22742892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; De Keyser J
    Eur J Neurol; 2012 Apr; 19(4):616-24. PubMed ID: 22117611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.
    Alroughani R; Ashkanani A; Lamdhade S
    Int J Neurosci; 2012 Feb; 122(2):82-7. PubMed ID: 21985585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
    Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.